Analyst Research Report On: Netflix (NFLX), Horizon Pharma (HZNP), Affymetrix Inc, (AFFX)
(firmenpresse) - PALM BEACH, FLORIDA -- (Marketwire) -- 10/08/12 -- Please Note: The following is an investment opinion issued by
Netflix (NASDAQ - NFLX)- Netflix, Inc. provides Internet subscription services for TV shows and movies in the United States and internationally. The company offers its subscribers to watch unlimited TV shows and movies streamed over the Internet to their TVs, computers, and mobile devices. Amazon has just released its new video service. But many analysts say that this won't have an impact on Netflix's business. Morgan Stanley has just upgraded the stock from "over weight" to "equal weight". Saying that just Netflix's domestic business justifies it's current evaluation. For more information on similar stocks click here.
Horizon Pharma (NASDAQ - HZNP) - Horizon Pharma, Inc., a biopharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Lets first start off by saying that not too long ago Horizon Pharma was trading at $8.00. Here are a little more recent positives on (HZNP). Just recently an insider just purchased 2mm in new shares. If that's not enough they just expanded their sales force from 80-150 to help push their drug Rayos that got FDA approval in July. Is HZNP a Buy? Click here to find out.
Affymetrix (AFFX) - Affymetrix, Inc. Engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets primarily in the United States, Europe, Japan. The company today reported that they expected revenues of approximately $80 million for the 3rd quarter. The company believes that revs for the 3rd quarter were negatively impacted due to tightening of "Academic funding" as well as a weaker euro. They wet as far as to say that revs should be flat or slightly down for 2012 compared to previous years.
To receive real time newsletters click here -
We invite you to join the newsletter, and see for yourself how so many have huge profits. There is no fee to join, and no obligation. Simply sign up for free and start receiving our exclusive alerts for a limited time.
If we had to sum up the benefit of our services in two simple words, they would be time and knowledge. We provide advanced notice, which is critical in the small-cap market, along with detailed reports. Unlike our competitors, we will only alert you to companies we believe in strongly and will not clog your inbox with useless information. The true value of our services is fully realized through a premium membership, which provides you with exclusive research in rapid fashion.
Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Stock Publisher is a wholly owned entity of a financial public relations firm. Please read our report and visit our website, for complete risks and disclosures.
Contacts:
StockPublisher.com
433 plaza real Suite 275
Boca Raton, Fl, 33432
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.10.2012 - 14:07 Uhr
Sprache: Deutsch
News-ID 190323
Anzahl Zeichen: 0
contact information:
Town:
PALM BEACH, FLORIDA
Kategorie:
Investment Opinion
Diese Pressemitteilung wurde bisher 303 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Analyst Research Report On: Netflix (NFLX), Horizon Pharma (HZNP), Affymetrix Inc, (AFFX)"
steht unter der journalistisch-redaktionellen Verantwortung von
StockPublisher.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
